Overview

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee

Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to characterize the local duration of exposure of TCA for 2 doses of FX006 relative to 40 mg of TCA IR in patients with OA of the knee.
Phase:
Phase 2
Details
Lead Sponsor:
Flexion Therapeutics, Inc.
Treatments:
FX006
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide